

* * * * * STN Columbus *
* * * * *

FILE 'HOME' ENTERED ON 23 NOV 1998

=> file uspatfull

=> s ((tumor? necros? factor?) or
tnf?)(5a)receptor?

24416 TUMOR?
7979 NECROS?
432703 FACTOR?
2469 TUMOR? NECROS? FACTOR?
(TUMOR?(W)NECROS?(W)FACTOR?)
2875 TNF?
35182 RECEPTOR?
L1 405 ((TUMOR? NECROS? FACTOR?) OR
TNF?)(5A)RECEPTOR?

=> d 1-20

L1 ANSWER 1 OF 405 USPATFULL
AN 1998:144233 USPATFULL
TI Nucleic acids molecules encoding
Caspase-8h and Caspase-8i
IN Hunter, John J., Cambridge, MA, United
States
Shyjan, Andrew W., Nahant, MA, United
States
Wong, Grace H. W., Brookline, MA,
United States
PA Millennium Pharmaceuticals, Inc.,
Cambridge, MA, United States
(U.S. corporation)
PI US 5837837 981117
AI US 97-807200 970227 (8)
DT Utility
LN.CNT 2079
INCL INCLM: 536/023.100
INCLS: 530/300.000; 530/350.000
NCL NCLM: 536/023.100
NCLS: 530/300.000; 530/350.000
IC [6]
ICM: C07H021-02
ICS: A61K038-00; C07K001-00
EXF 536/23.1; 530/350; 435/172.3;
435/69.1; 435/325; 424/93.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 2 OF 405 USPATFULL
AN 1998:144213 USPATFULL
TI **Tumor necrosis factor**
receptor-II-associated protein kinase
and methods for its
use
IN Aggarwal, Bharat B., Houston, TX,
United States
Darnay, Bryant G., Houston, TX, United
States
PA Research Development Foundation,
Carson City, NV, United States
(U.S. corporation)
PI US 5837817 981117
AI US 96-588604 960118 (8)
RLI Continuation-in-part of Ser. No. US
94-272005, filed on 7 Jul
1994, now abandoned
DT Utility
LN.CNT 953
INCL INCLM: 530/350.000
INCLS: 530/351.000; 435/194.000
NCL NCLM: 530/350.000

NCLS: 530/351.000; 435/194.000
IC [6]
ICM: C07K014-705
EXF 435/194; 530/350; 530/351

L1 ANSWER 3 OF 405 USPATFULL
AN 1998:144212 USPATFULL
TI Interleukin-2 receptor subunit
ectodomain fusion protein
comprising a leucine zipper domain
IN Ciardelli, Thomas L., Sharon, VT,
United States
Johnson, Kirk, Moraga, CA, United
States
PA Chiron Corporation, Emeryville, CA,
United States (U.S.
corporation)
Trustee of Dartmouth College, Hanover,
NH, United States (U.S.
corporation)
PI US 5837816 981117
AI US 95-474741 950607 (8)
RLI Continuation-in-part of Ser. No. US
95-438259, filed on 10 May
1995, now abandoned
DT Utility
LN.CNT 1970
INCL INCLM: 530/350.000
INCLS: 435/069.100; 435/320.100;
536/023.400; 536/024.100;
514/002.000
NCL NCLM: 530/350.000
NCLS: 435/069.100; 435/320.100;
536/023.400; 536/024.100;
514/002.000
IC [6]
ICM: C07K014-435
ICS: C07K014-705; C07K014-715;
C12N015-12
EXF 530/350; 435/69.1; 435/320.1;
435/240.2; 435/325; 435/7.1;
536/23.4; 514/2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 405 USPATFULL
AN 1998:144102 USPATFULL
TI Amino-alcohol substituted cyclic
compounds
IN Kumar, Anil M., Seattle, WA, United
States
Michnick, John, Seattle, WA, United
States
Underiner, Gail E., Brier, WA, United
States
Klein, J. Peter, Vashon Island, WA,
United States
Rice, Glenn C., Seattle, WA, United
States
PA Cell Therapeutics, Inc., Seattle, WA,
United States (U.S.
corporation)
PI US 5837703 981117
AI US 93-152650 931112 (8)
RLI Continuation-in-part of Ser. No. US
93-40820, filed on 31 Mar
1993, now abandoned
DT Utility
LN.CNT 2596
INCL INCLM: 514/183.000
INCLS: 514/211.000; 514/228.800;
514/241.000; 514/242.000;
514/249.000; 514/256.000;
514/259.000; 514/263.000;
514/270.000; 514/274.000;
514/309.000; 514/312.000;

514/315.000; 514/348.000;
 514/357.000; 514/374.000;
 514/400.000; 514/425.000;
 514/427.000; 540/467.000;
 540/544.000; 544/216.000;
 544/257.000; 544/272.000;
 544/286.000; 544/301.000;
 544/311.000; 544/335.000;
 546/096.000; 546/141.000;
 546/142.000; 546/157.000;
 546/246.000; 546/296.000;
 546/334.000; 548/215.000;
 548/340.100; 548/485.000;
 548/546.000; 548/561.000
 NCL NCLM: 514/183.000
 NCLS: 514/211.000; 514/228.800;
 514/241.000; 514/242.000;
 514/249.000; 514/256.000;
 514/259.000; 514/263.000;
 514/270.000; 514/274.000;
 514/309.000; 514/312.000;
 514/315.000; 514/348.000;
 514/357.000; 514/374.000;
 514/400.000; 514/425.000;
 514/427.000; 540/467.000;
 540/544.000; 544/216.000;
 544/257.000; 544/272.000;
 544/286.000; 544/301.000;
 544/311.000; 544/335.000;
 546/096.000; 546/141.000;
 546/142.000; 546/157.000;
 546/246.000; 546/296.000;
 546/334.000; 548/215.000;
 548/340.100; 548/485.000;
 548/546.000; 548/561.000
 IC [6]
 ICM: A61K031-55
 ICS: A61K031-515; A61K031-445;
 A61K031-52
 EXF 544/276; 544/272; 544/216; 544/257;
 544/285; 544/286; 544/301;
 544/311; 544/335; 514/263; 514/183;
 514/211; 514/228.8; 514/241;
 514/242; 514/249; 514/256; 514/259;
 514/270; 514/274; 514/309;
 514/312; 514/315; 514/348; 514/357;
 514/374; 514/400; 514/418;
 514/425; 514/427; 540/467; 540/544;
 546/96; 546/141; 546/142;
 546/157; 546/246; 546/296; 546/334;
 548/215; 548/340.1; 548/485;
 548/546; 548/561
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 405 USPATFULL
 AN 1998:143939 USPATFULL
 TI Expression of human multidrug
 resistance genes and improved
 selection of cells transduced with
 such genes
 IN McDonagh, Kevin T., Silver Spring, MD,
 United States
 Nienhuis, Arthur, Bethesda, MD, United
 States
 Tolstoshev, Paul, Potomac, MD, United
 States
 PA Genetic Therapy, Inc., Gaithersburg,
 MD, United States (U.S.
 corporation)
 The United States of America as
 represented by the Department of
 Health and Human Services, Washington,
 DC, United States (U.S.
 government)
 PI US 5837536 981117

AI US 96-583276 960105 (8)
 RLI Continuation of Ser. No. US 94-332444,
 filed on 31 Oct 1994, now
 abandoned which is a continuation of
 Ser. No. US 92-887712, filed
 on 22 May 1992, now abandoned
 DT Utility
 LN.CNT 1231
 INCL INCLM: 435/325.000
 INCLS: 536/023.500; 435/069.100;
 435/320.100
 NCL NCLM: 435/325.000
 NCLS: 536/023.500; 435/069.100;
 435/320.100
 IC [6]
 ICM: C12N005-22
 ICS: C12N015-12; C12N015-86
 EXF 536/23.1; 435/69.1; 435/320.1;
 435/240.2; 435/325

L1 ANSWER 6 OF 405 USPATFULL
 AN 1998:143904 USPATFULL
 TI Directed evolution of novel binding
 proteins
 IN Ladner, Robert Charles, Ijamsville,
 MD, United States
 Guttermann, Sonia Kosow, Belmont, MA,
 United States
 Roberts, Bruce Lindsay, Milford, MA,
 United States
 Markland, William, Milford, MA, United
 States
 Ley, Arthur Charles, Newton, MA,
 United States
 Kent, Rachel Baribault, Boxborough,
 MA, United States
 PA Dyax, Corp., Cambridge, MA, United
 States (U.S. corporation)
 PI US 5837500 981117
 AI US 95-415922 950403 (8)
 RLI Continuation of Ser. No. US 93-9319,
 filed on 26 Jan 1993, now
 patented, Pat. No. US 5403484 which is
 a division of Ser. No. US
 91-664989, filed on 1 Mar 1991, now
 patented, Pat. No. US 5223409
 which is a continuation-in-part of
 Ser. No. US 90-487063, filed on
 2 Mar 1990, now abandoned which is a
 continuation-in-part of Ser.
 No. US 88-240160, filed on 2 Sep 1988,
 now abandoned
 DT Utility
 LN.CNT 15973
 INCL INCLM: 435/069.700
 INCLS: 435/172.300; 530/350.000;
 530/412.000; 536/023.400
 NCL NCLM: 435/069.700
 NCLS: 435/172.300; 530/350.000;
 530/412.000; 536/023.400
 IC [6]
 ICM: C12N015-62
 ICS: C07K019-00
 EXF 435/69.7; 435/172.3; 530/350; 530/412;
 536/23.4

L1 ANSWER 7 OF 405 USPATFULL
 AN 1998:143875 USPATFULL
 TI Method of recovering a biological
 molecule from a recombinant
 microorganism
 IN Carlson, Peter S., Alexandria, VA,
 United States
 Quintero, Ernesto J., McLean, VA,
 United States

Manyak, David M., Ellicott City, MD,
United States
Chmurny, Alan B., Frederick, MD,
United States
PA Oceanix Biosciences Corporation,
Hanover, MD, United States (U.S.
corporation)

PI US 5837470 981117
AI US 98-21984 980211
RLI Division of Ser. No. US 96-766308,
filed on 13 Dec 1996
DT Utility
LN.CNT 1493
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/172.300;
435/172.200; 435/252.300
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/172.300;
435/172.200; 435/252.300
IC [6]
ICM: C12Q001-68
ICS: C12P021-02
EXF 435/6; 435/69.1; 435/172.2; 435/172.3;
435/252.3

L1 ANSWER 8 OF 405 USPATFULL
AN 1998:139020 USPATFULL
TI Chimeric viral receptor polypeptides
IN Meruelo, Daniel, Scarborough, NY,
United States

Yoshimoto, Takayuki, Tokyo, Japan
PA New York University, New York, NY,
United States (U.S.
corporation)

PI US 5834589 981110
AI US 93-132990 931007 (8)
RLI Continuation-in-part of Ser. No. US
93-84729, filed on 29 Jun
1993, now abandoned which is a
continuation-in-part of Ser. No. US
92-899075, filed on 11 Jun 1992, now
abandoned which is a
continuation-in-part of Ser. No. US
91-806178, filed on 13 Dec
1991, now abandoned which is a
continuation-in-part of Ser. No. US
90-627950, filed on 14 Dec 1990, now
abandoned

DT Utility
LN.CNT 3800
INCL INCLM: 530/350.000
INCLS: 530/387.300; 530/388.300;
530/389.100; 530/826.000;
435/171.300
NCL NCLM: 530/350.000
NCLS: 530/387.300; 530/388.300;
530/389.100; 530/826.000;
435/171.300

IC [6]
ICM: C12N015-00
ICS: C12P021-08; C07K016-00; C07K014-
00
EXF 530/350; 530/387.3; 530/387.1;
530/387.7

L1 ANSWER 9 OF 405 USPATFULL
AN 1998:138917 USPATFULL
TI Quinoline sulfonamides and their
therapeutic use
IN Dyke, Hazel Joan, Cambridge, United
Kingdom
Montana, John Gary, Cambridge, United
Kingdom
PA Chiroscience Limited, United Kingdom
(non-U.S. corporation)

PI US 5834485 981110
AI US 97-858969 970520 (8)
PRAI GB 96-10506 960520
GB 96-23234 961107
GB 96-26883 961224
GB 97-8071 970422

DT Utility
LN.CNT 732
INCL INCLM: 514/311.000
INCLS: 514/312.000; 514/313.000;
514/314.000; 546/153.000;
546/155.000; 546/156.000;
546/157.000; 546/159.000;
546/160.000; 546/168.000;
546/169.000; 546/170.000;
546/172.000

NCL NCLM: 514/311.000
NCLS: 514/312.000; 514/313.000;
514/314.000; 546/153.000;
546/155.000; 546/156.000;
546/157.000; 546/159.000;
546/160.000; 546/168.000;
546/169.000; 546/170.000;
546/172.000

IC [6]
ICM: C07D215-36
ICS: A61K031-47
EXF 546/154; 546/155; 546/156; 546/157;
546/160; 546/162; 546/172;
514/311; 514/312; 514/313; 514/314

L1 ANSWER 10 OF 405 USPATFULL
AN 1998:138868 USPATFULL
TI Inhibition of TNF-.alpha. pleiotropic
and cytotoxic effects
IN Slesarev, Vladimir I., 20 Colebrook
La., Conroe, TX, United States
77304

PI US 5834435 981110
AI US 96-757477 961127 (8)
DT Utility
LN.CNT 611
INCL INCLM: 514/019.000
INCLS: 514/008.000; 514/016.000;
514/921.000; 514/885.000;
530/322.000
NCL NCLM: 514/019.000
NCLS: 514/008.000; 514/016.000;
514/921.000; 514/885.000;
530/322.000

IC [6]
ICM: A61K038-05
EXF 514/19; 514/8; 514/16; 514/921;
514/885; 530/322

L1 ANSWER 11 OF 405 USPATFULL
AN 1998:138853 USPATFULL
TI Chemokine binding protein and methods
of use therefor
IN McFadden, Grant, Edmonton, Canada
Lucas, Alexandra, Edmonton, Canada
PA The John P. Roberts Institute, London,
Canada (non-U.S.
corporation)

PI US 5834419 981110
AI US 96-634924 960419 (8)
RLI Continuation-in-part of Ser. No. US
95-424850, filed on 19 Apr
1995, now abandoned
DT Utility
LN.CNT 1033
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000;
530/350.000; 424/084.000
NCL NCLM: 514/002.000

NCLS: 514/008.000; 514/012.000;
 530/350.000; 424/084.000
 IC [6]
 ICM: C61K038-16
 ICS: C07K014-065
 EXF 530/350; 514/2; 514/8; 514/12; 424/84

L1 ANSWER 12 OF 405 USPATFULL
 AN 1998:138709 USPATFULL
 TI Regulated apoptosis
 IN Crabtree, Gerald R., Woodside, CA,
 United States
 Schreiber, Stuart L., Cambridge, MA,
 United States
 Spencer, David M., Los Altos, CA,
 United States
 Wandless, Thomas J., Cambridge, MA,
 United States
 Belshaw, Peter, Somerville, MA, United
 States
 PA President & Fellows of Harvard
 College, Cambridge, MA, United
 States (U.S. corporation)
 Board of Trustees of Leland Stanford
 Jr. University, Stanford, CA,
 United States (U.S. corporation)
 PI US 5834266 981110
 AI US 94-292597 940818 (8)
 RLI Continuation-in-part of Ser. No. US
 94-179143, filed on 7 Jan
 1994, now abandoned And Ser. No. US
 94-179748, filed on 7 Jan 1994
 which is a continuation-in-part of
 Ser. No. US 93-92977, filed on
 16 Jul 1993, now abandoned which is a
 continuation-in-part of Ser.
 No. US 93-17931, filed on 12 Feb 1993,
 now abandoned, said Ser.
 No. US -179143 which is a
 continuation-in-part of Ser. No. US
 93-93499, filed on 16 Jul 1993
 DT Utility
 LN.CNT 5242
 INCL INCLM: 435/172.300
 INCLS: 435/320.100; 435/325.000;
 435/366.000; 536/234.000
 NCL NCLM: 435/172.300
 NCLS: 435/320.100; 435/325.000;
 435/366.000; 536/234.000
 IC [6]
 ICM: C12N015-62
 ICS: C12N015-63; C12N015-79; C12N005-
 10
 EXF 424/93.21; 514/44; 435/69.7;
 435/240.2; 435/320.1; 435/23.4;
 435/23.5; 435/325; 435/366; 435/372.3;
 435/172.3; 536/23.4;
 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 13 OF 405 USPATFULL
 AN 1998:138693 USPATFULL
 TI Method for identifying active domains
 and amino acid residues in
 polypeptides and hormone variants
 IN Wells, James A., Burlingame, CA,
 United States
 Cunningham, Brian C., Piedmont, CA,
 United States
 PA Genentech, Inc., South San Francisco,
 CA, United States (U.S.
 corporation)
 PI US 5834250 981110
 AI US 97-903398 970630 (8)

RLI Continuation of Ser. No. US 95-483039,
 filed on 6 Jun 1995, now
 patented, Pat. No. US 5766854 which is
 a continuation of Ser. No.
 US 94-190723, filed on 2 Feb 1994, now
 patented, Pat. No. US
 5580723 which is a continuation of
 Ser. No. US 92-960227, filed on
 13 Oct 1992, now abandoned which is a
 continuation of Ser. No. US
 92-875204, filed on 27 Apr 1992, now
 abandoned which is a
 continuation of Ser. No. US 89-428066,
 filed on 26 Oct 1989, now
 abandoned which is a continuation-in-
 part of Ser. No. US
 88-264611, filed on 28 Oct 1988, now
 abandoned
 DT Utility
 LN.CNT 3240
 INCL INCLM: 435/007.100
 INCLS: 435/004.000; 435/006.000;
 436/501.000; 530/300.000;
 530/326.000
 NCL NCLM: 435/007.100
 NCLS: 435/004.000; 435/006.000;
 436/501.000; 530/300.000;
 530/326.000
 IC [6]
 ICM: G01N033-53
 ICS: G01N033-566
 EXF 435/7.1; 435/4; 435/6; 435/69.1;
 435/71.1; 436/501; 530/300;
 530/326; 530/350; 530/387.1;
 530/388.1; 530/399; 530/806; 530/808

L1 ANSWER 14 OF 405 USPATFULL
 AN 1998:138593 USPATFULL
 TI Composition of photoconductive layer
 for a color display panel
 IN Kim, Min Ho, Suwon-si, Korea, Republic
 of
 Park, Wan Woo, Suwon-si, Korea,
 Republic of
 PA Samsung Display Devices Co., Ltd.,
 Suwon-si, Korea, Republic of
 (non-U.S. corporation)
 PI US 5834144 981110
 AI US 97-935443 970923 (8)
 PRAI KR 96-61603 961204
 KR 96-61606 961204
 DT Utility
 LN.CNT 378
 INCL INCLM: 430/028.000
 NCL NCLM: 430/028.000
 IC [6]
 ICM: G03C005-00
 EXF 430/28; 430/58; 430/59

L1 ANSWER 15 OF 405 USPATFULL
 AN 1998:135173 USPATFULL
 TI Interleukin-8 anti-peptide antibodies
 IN Schraufstatter, Ingrid U., San Diego,
 CA, United States
 Cochran, Charles G., La Jolla, CA,
 United States
 PA The Scripps Research Institute, La
 Jolla, CA, United States (U.S.
 corporation)
 PI US 5831032 981103
 AI US 96-643515 960506 (8)
 RLI Division of Ser. No. US 94-342348,
 filed on 21 Nov 1994, now
 abandoned which is a continuation of
 Ser. No. US 91-755824, filed

on 6 Sep 1991, now abandoned which is
a continuation-in-part of
Ser. No. US 90-581673, filed on 12 Sep
1990, now abandoned

DT Utility

LN.CNT 1372

INCL INCLM: 530/387.900

INCLS: 530/388.100; 530/388.230;

530/389.200; 530/326.000;

530/412.000; 530/413.000

NCL NCLM: 530/387.900

NCLS: 530/388.100; 530/388.230;

530/389.200; 530/326.000;

530/412.000; 530/413.000

IC [6]

ICM: C07K016-24

EXF 560/387.1; 560/388.1; 560/388.25;

560/389.2; 560/387.9; 560/326;

514/412; 514/413

L1 ANSWER 16 OF 405 USPATFULL

AN 1998:135151 USPATFULL

TI Human receptor for interleukin-12

IN Chua, Anne On, Wayne, NJ, United

States

Gubler, Ulrich Andreas, Glen Ridge,

NJ, United States

PA Hoffmann-La Roche Inc., Nutley, NJ,

United States (U.S.

corporation)

PI US 5831007 981103

AI US 95-419652 950411 (8)

RLI Division of Ser. No. US 94-248532,

filed on 31 May 1994, now

patented, Pat. No. US 5536657 which is

a continuation-in-part of

Ser. No. US 93-94713, filed on 19 Jul

1993, now abandoned

DT Utility

LN.CNT 1929

INCL INCLM: 530/350.000

INCLS: 530/351.000; 514/002.000;

514/008.000

NCL NCLM: 530/350.000

NCLS: 530/351.000; 514/002.000;

514/008.000

IC [6]

ICM: C07K014-715

EXF 514/2; 514/8; 530/350; 530/351

L1 ANSWER 17 OF 405 USPATFULL

AN 1998:135009 USPATEFULL

TI Peptides with bactericidal activity

and endotoxin neutralizing

activity for gram negative bacteria

and methods for their use

IN Gray, Beulah H., St. Paul, MN, United

States

Haseman, Judith R., Eagan, MN, United

States

Mayo, Kevin H., Minnetonka, MN, United

States

PA Regents of the University of

Minnesota, Minneapolis, MN, United

States (U.S. corporation)

PI US 5830860 981103

AI US 96-653632 960524 (8)

RLI Continuation-in-part of Ser. No. US

94-218026, filed on 24 Mar

1994

DT Utility

LN.CNT 3083

INCL INCLM: 514/012.000

INCLS: 514/013.000; 514/014.000;

514/015.000; 514/021.000;

435/069.700

NCL NCLM: 514/012.000

NCLS: 514/013.000; 514/014.000;

514/015.000; 514/021.000;

435/069.700

IC [6]

ICM: A61K038-08

ICS: A61K038-10; A61K038-17

EXF 514/12; 514/13; 514/14; 514/15;

514/21; 435/69.7

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 18 OF 405 USPATFULL

AN 1998:134631 USPATFULL

TI Fas antagonists and uses thereof

IN Lynch, David H., Bainbridge Island,

WA, United States

Alderson, Mark R., Bainbridge Island,

WA, United States

PA Immunex Corporation, Seattle, WA,

United States (U.S. corporation)

PI US 5830469 981103

AI US 95-429499 950426 (8)

RLI Continuation-in-part of Ser. No. US

94-322805, filed on 13 Oct

1994, now patented, Pat. No. US

5620889 which is a

continuation-in-part of Ser. No. US

93-159003, filed on 29 Nov

1993, now abandoned which is a

continuation-in-part of Ser. No. US

93-136817, filed on 14 Oct 1993, now

abandoned

DT Utility

LN.CNT 1993

INCL INCLM: 424/144.100

INCLS: 424/143.100; 424/153.100;

424/154.100; 424/155.100;

424/156.100; 530/388.200;

530/388.220; 530/388.230;

530/388.240; 435/332.000

NCL NCLM: 424/144.100

NCLS: 424/143.100; 424/153.100;

424/154.100; 424/155.100;

424/156.100; 530/388.200;

530/388.220; 530/388.230;

530/388.240; 435/332.000

IC [6]

ICM: A16K039-395

ICS: A16K035-12; C07K016-18; C12N005-

12

EXF 424/141.1; 424/154.1; 424/143.1;

424/140.1; 424/144.1; 424/155.1;

424/156.1; 424/153.1; 530/388.1;

530/387.1; 530/388.73;

530/388.75; 530/388.2; 530/388.22;

530/388.23; 530/388.24; 435/332

L1 ANSWER 19 OF 405 USPATFULL

AN 1998:134626 USPATFULL

TI Regulated transcription of targeted

genes and other biological

events

IN Crabtree, Gerald R., Woodside, CA,

United States

Schreiber, Stuart L., Cambridge, MA,

United States

Spencer, David M., Los Altos, CA,

United States

Wandless, Thomas J., Cambridge, MA,

United States

Belshaw, Peter, Cambridge, MA, United

States

PA President & Fellows of Harvard

College, Cambridge, MA, United

States (U.S. corporation)
Board of Trustees of Leland S.
Stanford, Jr. University, Stanford,
CA, United States (U.S. corporation)
PI US 5830462 981103
AI US 95-478386 950607 (8)
RLI Division of Ser. No. US 95-388653,
filed on 14 Feb 1995 And a
continuation-in-part of Ser. No. US
94-292597, filed on 18 Aug
1994 which is a continuation-in-part
of Ser. No. US 94-179748,
filed on 7 Jan 1994, now abandoned
which is a continuation-in-part
of Ser. No. US 93-92977, filed on 16
Jul 1993, now abandoned which
is a continuation-in-part of Ser. No.
US 93-17931, filed on 12 Feb
1993, now abandoned, said Ser. No. US
-388653 which is a
continuation-in-part of Ser. No. US
94-196043, filed on 11 Feb
1994 which is a continuation-in-part
of Ser. No. US -179748
which is a continuation-in-part of
Ser. No. US -92977 which is a
continuation-in-part of Ser. No. US
-17931
DT Utility
LN.CNT 4524
INCL INCLM: 424/093.210
INCLS: 435/172.300; 514/044.000
NCL NCLM: 424/093.210
NCLS: 435/172.300; 514/044.000
IC [6]
ICM: C12N015-63
ICS: A61K031-70; A61K048-00
EXF 435/69.1; 435/69.7; 435/240.2;
435/320.1; 435/172.3; 935/34;
935/36; 935/70; 935/71; 424/93.21;
514/44
L1 ANSWER 20 OF 405 USPATFULL
AN 1998:134612 USPATFULL
TI Compositions and methods for the
treatment of tumors
IN Vehar, Gordon A., San Carlos, CA,
United States
PA Genentech, Inc., South San Francisco,
CA, United States (U.S.
corporation)
PI US 5830448 981103
AI US 95-470777 950606 (8)
RLI Division of Ser. No. US 94-260850,
filed on 16 Jun 1994
DT Utility
LN.CNT 1698
INCL INCLM: 424/085.200
INCLS: 514/002.000; 530/351.000;
530/381.000; 424/085.500;
424/085.100
NCL NCLM: 424/085.200
NCLS: 514/002.000; 530/351.000;
530/381.000; 424/085.500;
424/085.100
IC [6]
ICM: A61K045-05
ICS: A61K038-00
EXF 514/2; 530/351; 530/381; 424/85.2;
424/85.5; 424/85.1
=> s 11 and (clon? or cdna?)

23616 CLON?
10407 CDNA?

L2 292 L1 AND (CLON? OR CDNA?)
=> d 1-20
L2 ANSWER 1 OF 292 USPATFULL
AN 1998:144233 USPATFULL
TI Nucleic acids molecules encoding
Caspase-8h and Caspase-8i
IN Hunter, John J., Cambridge, MA, United
States
Shyjan, Andrew W., Nahant, MA, United
States
Wong, Grace H. W., Brookline, MA,
United States
PA Millennium Pharmaceuticals, Inc.,
Cambridge, MA, United States
(U.S. corporation)
PI US 5837837 981117
AI US 97-807200 970227 (8)
DT Utility
LN.CNT 2079
INCL INCLM: 536/023.100
INCLS: 530/300.000; 530/350.000
NCL NCLM: 536/023.100
NCLS: 530/300.000; 530/350.000
IC [6]
ICM: C07H021-02
ICS: A61K038-00; C07K001-00
EXF 536/23.1; 530/350; 435/172.3;
435/69.1; 435/325; 424/93.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L2 ANSWER 2 OF 292 USPATFULL
AN 1998:144213 USPATFULL
TI **Tumor necrosis factor**
receptor-II-associated protein kinase
and methods for its
use
IN Aggarwal, Bharat B., Houston, TX,
United States
Darnay, Bryant G., Houston, TX, United
States
PA Research Development Foundation,
Carson City, NV, United States
(U.S. corporation)
PI US 5837817 981117
AI US 96-588604 960118 (8)
RLI Continuation-in-part of Ser. No. US
94-272005, filed on 7 Jul
1994, now abandoned
DT Utility
LN.CNT 953
INCL INCLM: 530/350.000
INCLS: 530/351.000; 435/194.000
NCL NCLM: 530/350.000
NCLS: 530/351.000; 435/194.000
IC [6]
ICM: C07K014-705
EXF 435/194; 530/350; 530/351
L2 ANSWER 3 OF 292 USPATFULL
AN 1998:144212 USPATFULL
TI Interleukin-2 receptor subunit
ectodomain fusion protein
comprising a leucine zipper domain
IN Ciardelli, Thomas L., Sharon, VT,
United States
Johnson, Kirk, Moraga, CA, United
States
PA Chiron Corporation, Emeryville, CA,
United States (U.S.
corporation)

Trustee of Dartmouth College, Hanover,
NH, United States (U.S.
corporation)

PI US 5837816 981117.

AI US 95-474741 950607 (8)

RLI Continuation-in-part of Ser. No. US
95-438259, filed on 10 May

1995, now abandoned

DT Utility

LN.CNT 1970

INCL INCLM: 530/350.000

INCLS: 435/069.100; 435/320.100;

536/023.400; 536/024.100;

514/002.000

NCL NCLM: 530/350.000

NCLS: 435/069.100; 435/320.100;

536/023.400; 536/024.100;

514/002.000

IC [6]

ICM: C07K014-435

ICS: C07K014-705; C07K014-715;

C12N015-12

EXF 530/350; 435/69.1; 435/320.1;

435/240.2; 435/325; 435/7.1;

536/23.4; 514/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 4 OF 292 USPATFULL

AN 1998:144102 USPATFULL

TI Amino-alcohol substituted cyclic
compounds

IN Kumar, Anil M., Seattle, WA, United
States

Michnick, John, Seattle, WA, United
States

Underiner, Gail E., Brier, WA, United
States

Klein, J. Peter, Vashon Island, WA,
United States

Rice, Glenn C., Seattle, WA, United
States

PA Cell Therapeutics, Inc., Seattle, WA,
United States (U.S.

corporation)

PI US 5837703 981117

AI US 93-152650 931112 (8)

RLI Continuation-in-part of Ser. No. US
93-40820, filed on 31 Mar

1993, now abandoned

DT Utility

LN.CNT 2596

INCL INCLM: 514/183.000

INCLS: 514/211.000; 514/228.800;

514/241.000; 514/242.000;

514/249.000; 514/256.000;

514/259.000; 514/263.000;

514/270.000; 514/274.000;

514/309.000; 514/312.000;

514/315.000; 514/348.000;

514/357.000; 514/374.000;

514/400.000; 514/425.000;

514/427.000; 540/467.000;

540/544.000; 544/216.000;

544/257.000; 544/272.000;

544/286.000; 544/301.000;

544/311.000; 544/335.000;

546/096.000; 546/141.000;

546/142.000; 546/157.000;

546/246.000; 546/296.000;

546/334.000; 548/215.000;

548/340.100; 548/485.000;

548/546.000; 548/561.000

NCL NCLM: 514/183.000

NCLS: 514/211.000; 514/228.800;

514/241.000; 514/242.000;

514/249.000; 514/256.000;

514/259.000; 514/263.000;

514/270.000; 514/274.000;

514/309.000; 514/312.000;

514/315.000; 514/348.000;

514/357.000; 514/374.000;

514/400.000; 514/425.000;

514/427.000; 540/467.000;

540/544.000; 544/216.000;

544/257.000; 544/272.000;

544/286.000; 544/301.000;

544/311.000; 544/335.000;

546/096.000; 546/141.000;

546/142.000; 546/157.000;

546/246.000; 546/296.000;

546/334.000; 548/215.000;

548/340.100; 548/485.000;

548/546.000; 548/561.000

IC [6]

ICM: A61K031-55

ICS: A61K031-515; A61K031-445;

A61K031-52

EXF 544/276; 544/272; 544/216; 544/257;

544/285; 544/286; 544/301;

544/311; 544/335; 514/263; 514/183;

514/211; 514/228.8; 514/241;

514/242; 514/249; 514/256; 514/259;

514/270; 514/274; 514/309;

514/312; 514/315; 514/348; 514/357;

514/374; 514/400; 514/418;

514/425; 514/427; 540/467; 540/544;

546/96; 546/141; 546/142;

546/157; 546/246; 546/296; 546/334;

548/215; 548/340.1; 548/485;

548/546; 548/561

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 5 OF 292 USPATFULL

AN 1998:143939 USPATFULL

TI Expression of human multidrug
resistance genes and improved

selection of cells transduced with
such genes

IN McDonagh, Kevin T., Silver Spring, MD,
United States

Nienhuis, Arthur, Bethesda, MD, United
States

Tolstoshev, Paul, Potomac, MD, United
States

PA Genetic Therapy, Inc., Gaithersburg,
MD, United States (U.S.

corporation)

The United States of America as

represented by the Department of

Health and Human Services, Washington,
DC, United States (U.S.

government)

PI US 5837536 981117

AI US 96-583276 960105 (8)

RLI Continuation of Ser. No. US 94-332444,
filed on 31 Oct 1994, now

abandoned which is a continuation of
Ser. No. US 92-887712, filed

on 22 May 1992, now abandoned

DT Utility

LN.CNT 1231

INCL INCLM: 435/325.000

INCLS: 536/023.500; 435/069.100;

435/320.100

NCL NCLM: 435/325.000

NCLS: 536/023.500; 435/069.100;

435/320.100

IC [6]

ICM: C12N005-22

ICS: C12N015-12; C12N015-86

EXF 536/23.1; 435/69.1; 435/320.1;
435/240.2; 435/325

L2 ANSWER 6 OF 292 USPATFULL
AN 1998:143904 USPATFULL
TI Directed evolution of novel binding
proteins
IN Ladner, Robert Charles, Ijamsville,
MD, United States
United States
Gutterman, Sonia Kosow, Belmont, MA,
United States
Roberts, Bruce Lindsay, Milford, MA,
United States
Markland, William, Milford, MA, United
States
Ley, Arthur Charles, Newton, MA,
United States
Kent, Rachel Baribault, Boxborough,
MA, United States
PA Dyax, Corp., Cambridge, MA, United
States (U.S. corporation)
PI US 5837500 981117
AI US 95-415922 950403 (8)
RLI Continuation of Ser. No. US 93-9319,
filed on 26 Jan 1993, now
patented, Pat. No. US 5403484 which is
a division of Ser. No. US
91-664989, filed on 1 Mar 1991, now
patented, Pat. No. US 5223409
which is a continuation-in-part of
Ser. No. US 90-487063, filed on
2 Mar 1990, now abandoned which is a
continuation-in-part of Ser.
No. US 88-240160, filed on 2 Sep 1988,
now abandoned
DT Utility
LN.CNT 15973
INCL INCLM: 435/069.700
INCLS: 435/172.300; 530/350.000;
530/412.000; 536/023.400
NCL NCLM: 435/069.700
NCLS: 435/172.300; 530/350.000;
530/412.000; 536/023.400
IC [6]
ICM: C12N015-62
ICS: C07K019-00
EXF 435/69.7; 435/172.3; 530/350; 530/412;
536/23.4

L2 ANSWER 7 OF 292 USPATFULL
AN 1998:143875 USPATFULL
TI Method of recovering a biological
molecule from a recombinant
microorganism
IN Carlson, Peter S., Alexandria, VA,
United States
Quintero, Ernesto J., McLean, VA,
United States
Manyak, David M., Ellicott City, MD,
United States
Chmurny, Alan B., Frederick, MD,
United States
PA Oceanix Biosciences Corporation,
Hanover, MD, United States (U.S.
corporation)
PI US 5837470 981117
AI US 98-21984 980211
RLI Division of Ser. No. US 96-766308,
filed on 13 Dec 1996
DT Utility
LN.CNT 1493
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/172.300;
435/172.200; 435/252.300
NCL NCLM: 435/006.000

NCLS: 435/069.100; 435/172.300;
435/172.200; 435/252.300
IC [6]

ICM: C12Q001-68
ICS: C12P021-02
EXF 435/6; 435/69.1; 435/172.2; 435/172.3;
435/252.3

L2 ANSWER 8 OF 292 USPATFULL
AN 1998:139020 USPATFULL
TI Chimeric viral receptor polypeptides
IN Meruelo, Daniel, Scarborough, NY,
United States
Yoshimoto, Takayuki, Tokyo, Japan
PA New York University, New York, NY,
United States (U.S.
corporation)
PI US 5834589 981110
AI US 93-132990 931007 (8)
RLI Continuation-in-part of Ser. No. US
93-84729, filed on 29 Jun
1993, now abandoned which is a
continuation-in-part of Ser. No. US
92-899075, filed on 11 Jun 1992, now
abandoned which is a
continuation-in-part of Ser. No. US
91-806178, filed on 13 Dec
1991, now abandoned which is a
continuation-in-part of Ser. No. US
90-627950, filed on 14 Dec 1990, now
abandoned
DT Utility
LN.CNT 3800
INCL INCLM: 530/350.000
INCLS: 530/387.300; 530/388.300;
530/389.100; 530/826.000;
435/171.300
NCL NCLM: 530/350.000
NCLS: 530/387.300; 530/388.300;
530/389.100; 530/826.000;
435/171.300
IC [6]
ICM: C12N015-00
ICS: C12P021-08; C07K016-00; C07K014-
00
EXF 530/350; 530/387.3; 530/387.1;
530/387.7

L2 ANSWER 9 OF 292 USPATFULL
AN 1998:138853 USPATFULL
TI Chemokine binding protein and methods
of use therefor
IN McFadden, Grant, Edmonton, Canada
Lucas, Alexandra, Edmonton, Canada
PA The John P. Robarts Institute, London,
Canada (non-U.S.
corporation)
PI US 5834419 981110
AI US 96-634924 960419 (8)
RLI Continuation-in-part of Ser. No. US
95-424850, filed on 19 Apr
1995, now abandoned
DT Utility
LN.CNT 1033
INCL INCLM: 514/002.000
INCLS: 514/008.000; 514/012.000;
530/350.000; 424/084.000
NCL NCLM: 514/002.000
NCLS: 514/008.000; 514/012.000;
530/350.000; 424/084.000
IC [6]
ICM: C61K038-16
ICS: C07K014-065
EXF 530/350; 514/2; 514/8; 514/12; 424/84

L2 ANSWER 10 OF 292 USPATFULL
 AN 1998:138709 USPATFULL
 TI Regulated apoptosis.
 IN Crabtree, Gerald R., Woodside, CA,
 United States
 Schreiber, Stuart L., Cambridge, MA,
 United States
 Spencer, David M., Los Altos, CA,
 United States
 Wandless, Thomas J., Cambridge, MA,
 United States
 Belshaw, Peter, Somerville, MA, United
 States
 PA President & Fellows of Harvard
 College, Cambridge, MA, United
 States (U.S. corporation)
 Board of Trustees of Leland Stanford
 Jr. University, Stanford, CA,
 United States (U.S. corporation)
 PI US 5834266 981110
 AI US 94-292597 940818 (8)
 RLI Continuation-in-part of Ser. No. US
 94-179143, filed on 7 Jan
 1994, now abandoned And Ser. No. US
 94-179748, filed on 7 Jan 1994
 which is a continuation-in-part of
 Ser. No. US 93-92977, filed on
 16 Jul 1993, now abandoned which is a
 continuation-in-part of Ser.
 No. US 93-17931, filed on 12 Feb 1993,
 now abandoned, said Ser.
 No. US -179143 which is a
 continuation-in-part of Ser. No. US
 93-93499, filed on 16 Jul 1993
 DT Utility
 LN.CNT 5242
 INCL INCLM: 435/172.300
 INCLS: 435/320.100; 435/325.000;
 435/366.000; 536/234.000
 NCL NCLM: 435/172.300
 NCLS: 435/320.100; 435/325.000;
 435/366.000; 536/234.000
 IC [6]
 ICM: C12N015-62
 ICS: C12N015-63; C12N015-79; C12N005-
 10
 EXF 424/93.21; 514/44; 435/69.7;
 435/240.2; 435/320.1; 435/23.4;
 435/23.5; 435/325; 435/366; 435/372.3;
 435/172.3; 536/23.4;
 536/23.5
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 11 OF 292 USPATFULL
 AN 1998:138693 USPATFULL
 TI Method for identifying active domains
 and amino acid residues in
 polypeptides and hormone variants
 IN Wells, James A., Burlingame, CA,
 United States
 Cunningham, Brian C., Piedmont, CA,
 United States
 PA Genentech, Inc., South San Francisco,
 CA, United States (U.S.
 corporation)
 PI US 5834250 981110
 AI US 97-903398 970630 (8)
 RLI Continuation of Ser. No. US 95-483039,
 filed on 6 Jun 1995, now
 patented, Pat. No. US 5766854 which is
 a continuation of Ser. No.
 US 94-190723, filed on 2 Feb 1994, now
 patented, Pat. No. US
 5580723 which is a continuation of
 Ser. No. US 92-960227, filed on

13 Oct 1992, now abandoned which is a
 continuation of Ser. No. US
 92-875204, filed on 27 Apr 1992, now
 abandoned which is a
 continuation of Ser. No. US 89-428066,
 filed on 26 Oct 1989, now
 abandoned which is a continuation-in-
 part of Ser. No. US
 88-264611, filed on 28 Oct 1988, now
 abandoned
 DT Utility
 LN.CNT 3240
 INCL INCLM: 435/007.100
 INCLS: 435/004.000; 435/006.000;
 436/501.000; 530/300.000;
 530/326.000
 NCL NCLM: 435/007.100
 NCLS: 435/004.000; 435/006.000;
 436/501.000; 530/300.000;
 530/326.000
 IC [6]
 ICM: G01N033-53
 ICS: G01N033-566
 EXF 435/7.1; 435/4; 435/6; 435/69.1;
 435/71.1; 436/501; 530/300;
 530/326; 530/350; 530/387.1;
 530/388.1; 530/399; 530/806; 530/808

L2 ANSWER 12 OF 292 USPATFULL
 AN 1998:135173 USPATFULL
 TI Interleukin-8 anti-peptide antibodies
 IN Schraufstatter, Ingrid U., San Diego,
 CA, United States
 Cochrane, Charles G., La Jolla, CA,
 United States
 PA The Scripps Research Institute, La
 Jolla, CA, United States (U.S.
 corporation)
 PI US 5831032 981103
 AI US 96-643515 960506 (8)
 RLI Division of Ser. No. US 94-342348,
 filed on 21 Nov 1994, now
 abandoned which is a continuation of
 Ser. No. US 91-755824, filed
 on 6 Sep 1991, now abandoned which is
 a continuation-in-part of
 Ser. No. US 90-581673, filed on 12 Sep
 1990, now abandoned
 DT Utility
 LN.CNT 1372
 INCL INCLM: 530/387.900
 INCLS: 530/388.100; 530/388.230;
 530/389.200; 530/326.000;
 530/412.000; 530/413.000
 NCL NCLM: 530/387.900
 NCLS: 530/388.100; 530/388.230;
 530/389.200; 530/326.000;
 530/412.000; 530/413.000
 IC [6]
 ICM: C07K016-24
 EXF 560/387.1; 560/388.1; 560/388.25;
 560/389.2; 560/387.9; 560/326;
 514/412; 514/413

L2 ANSWER 13 OF 292 USPATFULL
 AN 1998:135151 USPATFULL
 TI Human receptor for interleukin-12
 IN Chua, Anne On, Wayne, NJ, United
 States
 Gubler, Ulrich Andreas, Glen Ridge,
 NJ, United States
 PA Hoffmann-La Roche Inc., Nutley, NJ,
 United States (U.S.
 corporation)
 PI US 5831007 981103

AI US 95-419652 950411 (8)
RLI Division of Ser. No. US 94-248532,
filed on 31 May 1994, now
patented, Pat. No. US 5536657 which is
a continuation-in-part of
Ser. No. US 93-94713, filed on 19 Jul
1993, now abandoned
DT Utility
LN.CNT 1929
INCL INCLM: 530/350.000
INCLS: 530/351.000; 514/002.000;
514/008.000
NCL NCLM: 530/350.000
NCLS: 530/351.000; 514/002.000;
514/008.000
IC [6]
ICM: C07K014-715
EXF 514/2; 514/8; 530/350; 530/351

L2 ANSWER 14 OF 292 USPTAFULL
AN 1998:135009 USPTAFULL
TI Peptides with bactericidal activity
and endotoxin neutralizing
activity for gram negative bacteria
and methods for their use
IN Gray, Beulah H., St. Paul, MN, United
States
Haseman, Judith R., Eagan, MN, United
States
Mayo, Kevin H., Minnetonka, MN, United
States
PA Regents of the University of
Minnesota, Minneapolis, MN, United
States (U.S. corporation)
PI US 5830860 981103
AI US 96-653632 960524 (8)
RLI Continuation-in-part of Ser. No. US
94-218026, filed on 24 Mar
1994
DT Utility
LN.CNT 3083
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000;
514/015.000; 514/021.000;
435/069.700
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000;
514/015.000; 514/021.000;
435/069.700
IC [6]
ICM: A61K038-08
ICS: A61K038-10; A61K038-17
EXF 514/12; 514/13; 514/14; 514/15;
514/21; 435/69.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 15 OF 292 USPTAFULL
AN 1998:134631 USPTAFULL
TI Fas antagonists and uses thereof
IN Lynch, David H., Bainbridge Island,
WA, United States
Alderson, Mark R., Bainbridge Island,
WA, United States
PA Immunex Corporation, Seattle, WA,
United States (U.S. corporation)
PI US 5830469 981103
AI US 95-429499 950426 (8)
RLI Continuation-in-part of Ser. No. US
94-322805, filed on 13 Oct
1994, now patented, Pat. No. US
5620889 which is a
continuation-in-part of Ser. No. US
93-159003, filed on 29 Nov
1993, now abandoned which is a
continuation-in-part of Ser. No. US

93-136817, filed on 14 Oct 1993, now
abandoned
DT Utility
LN.CNT 1993
INCL INCLM: 424/144.100
INCLS: 424/143.100; 424/153.100;
424/154.100; 424/155.100;
424/156.100; 530/388.200;
530/388.220; 530/388.230;
530/388.240; 435/332.000
NCL NCLM: 424/144.100
NCLS: 424/143.100; 424/153.100;
424/154.100; 424/155.100;
424/156.100; 530/388.200;
530/388.220; 530/388.230;
530/388.240; 435/332.000

IC [6]
ICM: A16K039-395
ICS: A16K035-12; C07K016-18; C12N005-
12
EXF 424/141.1; 424/154.1; 424/143.1;
424/140.1; 424/144.1; 424/155.1;
424/156.1; 424/153.1; 530/388.1;
530/387.1; 530/388.73;
530/388.75; 530/388.2; 530/388.22;
530/388.23; 530/388.24; 435/332

L2 ANSWER 16 OF 292 USPTAFULL
AN 1998:134626 USPTAFULL
TI Regulated transcription of targeted
genes and other biological
events
IN Crabtree, Gerald R., Woodside, CA,
United States
Schreiber, Stuart L., Cambridge, MA,
United States
Spencer, David M., Los Altos, CA,
United States
Wandless, Thomas J., Cambridge, MA,
United States
Belshaw, Peter, Cambridge, MA, United
States
PA President & Fellows of Harvard
College, Cambridge, MA, United
States (U.S. corporation)
Board of Trustees of Leland S.
Stanford, Jr. University, Stanford,
CA, United States (U.S. corporation)
PI US 5830462 981103
AI US 95-478386 950607 (8)
RLI Division of Ser. No. US 95-388653,
filed on 14 Feb 1995 And a
continuation-in-part of Ser. No. US
94-292597, filed on 18 Aug
1994 which is a continuation-in-part
of Ser. No. US 94-179748,
filed on 7 Jan 1994, now abandoned
which is a continuation-in-part
of Ser. No. US 93-92977, filed on 16
Jul 1993, now abandoned which
is a continuation-in-part of Ser. No.
US 93-17931, filed on 12 Feb
1993, now abandoned, said Ser. No. US
-388653 which is a
continuation-in-part of Ser. No. US
94-196043, filed on 11 Feb
1994 which is a continuation-in-part
of Ser. No. US -179748
which is a continuation-in-part of
Ser. No. US -92977 which is a
continuation-in-part of Ser. No. US
-17931
DT Utility
LN.CNT 4524
INCL INCLM: 424/093.210

INCLS: 435/172.300; 514/044.000
NCL NCLM: 424/093.210
NCLS: 435/172.300; 514/044.000
IC [6]
ICM: C12N015-63
ICS: A61K031-70; A61K048-00
EXF 435/69.1; 435/69.7; 435/240.2;
435/320.1; 435/172.3; 935/34;
935/36; 935/70; 935/71; 424/93.21;
514/44
L2 ANSWER 17 OF 292 USPATFULL
AN 1998:134612 USPATFULL
TI Compositions and methods for the
treatment of tumors
IN Vehar, Gordon A., San Carlos, CA,
United States
PA Genentech, Inc., South San Francisco,
CA, United States (U.S.
corporation)
PI US 5830448 981103
AI US 95-470777 950606 (8)
RLI Division of Ser. No. US 94-260850,
filed on 16 Jun 1994
DT Utility
LN.CNT 1698
INCL INCLM: 424/085.200
INCLS: 514/002.000; 530/351.000;
530/381.000; 424/085.500;
424/085.100
NCL NCLM: 424/085.200
NCLS: 514/002.000; 530/351.000;
530/381.000; 424/085.500;
424/085.100
IC [6]
ICM: A61K045-05
ICS: A61K038-00
EXF 514/2; 530/351; 530/381; 424/85.2;
424/85.5; 424/85.1
L2 ANSWER 18 OF 292 USPATFULL
AN 1998:128378 USPATFULL
TI Human stromelysin-1 promoter
IN Borden, Paula Ann, Palo Alto, CA,
United States
Heller, Renu Anand, Stanford, CA,
United States
PA Syntex (U.S.A.) Inc., Palo Alto, CA,
United States (U.S.
corporation)
PI US 5824794 981020
AI US 94-362706 941223 (8)
DT Utility
LN.CNT 812
INCL INCLM: 536/024.100
INCLS: 435/172.300; 435/320.100;
435/325.000; 435/366.000;
435/252.300; 536/023.500
NCL NCLM: 536/024.100
NCLS: 435/252.300; 435/320.100;
435/325.000; 435/366.000;
536/023.500
IC [6]
ICM: C07H021-04
ICS: C12N005-16; C12N015-12; C12N015-
85
EXF 514/44; 536/23.1; 536/24.1; 536/23.5;
435/320.1; 435/240.2; 435/6;
435/252.3; 435/366; 435/172.3;
435/325; 424/93.21
L2 ANSWER 19 OF 292 USPATFULL
AN 1998:128265 USPATFULL
TI Substituted amino alcohol compounds

IN Klein, J. Peter, Vashon, WA, United
States
Underiner, Gail E., Brier, WA, United
States
Kumar, Anil M., Seattle, WA, United
States
PA Cell Therapeutics, Inc., Seattle, WA,
United States (U.S.
corporation)
PI US 5824677 981020
AI US 95-474816 950607 (8)
RLI Division of Ser. No. US 94-303842,
filed on 8 Sep 1994, now
patented, Pat. No. US 5641783 which is
a continuation-in-part of
Ser. No. US 93-152650, filed on 12 Nov
1993, now patented, Pat.
No. US 5801181 And Ser. No. US 93-
164081, filed on 8 Dec 1993, now
patented, Pat. No. US 5470878, said
Ser. No. US -152650 And
Ser. No. US -164081, each Ser. No.
US - which is a
continuation-in-part of Ser. No. US
93-40820, filed on 31 Mar
1993, now abandoned
DT Utility
LN.CNT 3136
INCL INCLM: 514/222.500
INCLS: 514/223.500; 514/224.500;
514/226.800; 514/227.500;
514/228.800; 514/229.200;
514/230.500; 514/230.800;
514/237.800; 514/248.000;
514/249.000; 514/255.000;
514/258.000; 514/274.000;
514/301.000; 514/303.000;
514/311.000; 514/351.000;
514/360.000; 514/361.000;
514/362.000; 514/363.000;
514/364.000; 514/365.000;
514/367.000; 514/372.000;
514/373.000; 514/374.000;
514/375.000; 514/376.000;
514/378.000; 514/379.000;
514/380.000; 514/387.000;
514/395.000; 514/415.000;
514/418.000; 514/424.000;
514/425.000; 514/433.000;
514/452.000; 514/432.000;
514/438.000; 346/113.000;
346/114.000; 346/164.000;
346/300.000; 549/014.000;
549/050.000; 549/075.000;
549/367.000; 549/368.000;
544/002.000; 544/003.000;
544/005.000; 544/008.000;
544/053.000; 544/063.000;
544/065.000; 544/066.000;
544/067.000; 544/090.000;
544/091.000; 544/127.000;
544/128.000; 544/162.000;
544/215.000; 544/219.000;
544/229.000; 544/235.000;
544/237.000; 544/255.000;
544/278.000; 544/311.000;
544/353.000; 544/385.000;
548/123.000; 548/125.000;
548/131.000; 548/134.000;
548/143.000; 548/146.000;
548/153.000; 548/174.000;
548/207.000; 548/214.000;
548/215.000; 548/217.000;
548/221.000; 548/228.000;
548/229.000; 548/237.000;

548/240.000; 548/241.000;
 548/243.000; 548/247.000;
 548/267.200; 548/303.700;
 548/307.100; 548/453.000;
 548/486.000; 548/543.000;
 548/546.000
 NCL NCLM: 514/222.500
 NCLS: 514/223.500; 514/224.500;
 514/226.800; 514/227.500;
 514/228.800; 514/229.200;
 514/230.500; 514/230.800;
 514/237.800; 514/248.000;
 514/249.000; 514/255.000;
 514/258.000; 514/274.000;
 514/301.000; 514/303.000;
 514/311.000; 514/351.000;
 514/360.000; 514/361.000;
 514/362.000; 514/363.000;
 514/364.000; 514/365.000;
 514/367.000; 514/372.000;
 514/373.000; 514/374.000;
 514/375.000; 514/376.000;
 514/378.000; 514/379.000;
 514/380.000; 514/387.000;
 514/395.000; 514/415.000;
 514/418.000; 514/424.000;
 514/425.000; 514/432.000;
 514/433.000; 514/438.000;
 514/452.000; 544/002.000;
 544/003.000; 544/005.000;
 544/008.000; 544/053.000;
 544/063.000; 544/065.000;
 544/066.000; 544/067.000;
 544/090.000; 544/091.000;
 544/127.000; 544/128.000;
 544/162.000; 544/215.000;
 544/219.000; 544/229.000;
 544/235.000; 544/237.000;
 544/255.000; 544/278.000;
 544/311.000; 544/353.000;
 544/385.000; 546/113.000;
 546/114.000; 546/164.000;
 546/300.000; 548/123.000;
 548/125.000; 548/131.000;
 548/134.000; 548/143.000;
 548/146.000; 548/153.000;
 548/174.000; 548/207.000;
 548/214.000; 548/215.000;
 548/217.000; 548/221.000;
 548/228.000; 548/229.000;
 548/237.000; 548/240.000;
 548/241.000; 548/243.000;
 548/247.000; 548/267.200;
 548/303.700; 548/307.100;
 548/453.000; 548/486.000;
 548/543.000; 548/546.000;
 549/014.000; 549/050.000;
 549/075.000; 549/367.000;
 549/368.000
 IC [6]
 ICM: A61K031-385
 ICS: A61K031-445; A61K031-47; A61K031-
 505
 EXF 549/75; 549/50; 549/14; 549/367;
 549/368; 514/432; 514/438;
 514/222.5; 514/223.5; 514/224.5;
 514/226.8; 514/227.5; 514/228.8;
 514/229.2; 514/230.5; 514/230.8;
 514/237.8; 514/248; 514/249;
 514/255; 514/258; 514/274; 514/301;
 514/303; 514/311; 514/351;
 514/360; 514/361; 514/362; 514/363;
 514/364; 514/365; 514/367;
 514/372; 514/373; 514/374; 514/375;
 514/376; 514/378; 514/379;

514/380; 514/387; 514/395; 514/415;
 514/418; 514/424; 514/425;
 514/433; 514/452; 544/2; 544/3; 544/5;
 544/8; 544/53; 544/63;
 544/65; 544/66; 544/67; 544/90;
 544/91; 544/127; 544/128; 544/162;
 544/215; 544/219; 544/229; 544/235;
 544/237; 544/255; 544/278;
 544/311; 544/353; 544/385; 546/113;
 546/114; 546/164; 546/300;
 548/123; 548/125; 548/131; 548/134;
 548/145; 548/146; 548/153;
 548/174; 548/207; 548/214; 548/215;
 548/217; 548/221; 548/228;
 548/229; 548/237; 548/240; 548/241;
 548/243; 548/247; 548/267.2;
 548/303.7; 548/307.1; 548/453;
 548/486; 548/543; 548/546
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 20 OF 292 USPATFULL
 AN 1998:128224 USPATFULL
 TI Antiproliferative protein from
 Bacillus thuringiensis var.
 thuringiensis
 IN Aggarwal, Bharat B., Houston, TX,
 United States
 Rodriguez-Padilla, Cristina,
 Monterrey, Mexico
 PA Research Development Corporation,
 Carson City, NV, United States
 (U.S. corporation)
 Universidad Autonoma de Nuevo Leon,
 Nuevo Leon, Mexico (non-U.S.
 corporation)
 PI US 5824636 981020
 AI US 96-743553 961104 (8)
 RLI Continuation of Ser. No. US 95-454636,
 filed on 31 May 1995, now
 abandoned
 DT Utility
 LN.CNT 823
 INCL INCLM: 514/002.000
 INCLS: 530/350.000
 NCL NCLM: 514/002.000
 NCLS: 530/350.000
 IC [6]
 ICM: A61K039-07
 ICS: A61K038-16; C07K014-32
 530/350; 514/2; 424/93.461
 EXF
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> e greene john/au

E1	1	GREENE JOEL C/AU
E2	1	GREENE JOHATHAN W/AU
E3	2 -->	GREENE JOHN/AU
E4	3	GREENE JOHN D/AU
E5	1	GREENE JOHN F/AU
E6	1	GREENE JOHN L/AU
E7	4	GREENE JOHN M/AU
E8	2	GREENE JOHN P/AU
E9	1	GREENE JONATHAN/AU
E10	1	GREENE JONATHAN A/AU
E11	11	GREENE JONATHAN W/AU
E12	1	GREENE JOSEPH E/AU

=> s e7 and l1

	4	"GREENE JOHN M"/AU
L3	0	"GREENE JOHN M"/AU AND L1

=> e greene j/au

E1	1	GREENE IRWIN D/AU
----	---	-------------------

E2	1	GREENE IRWIN R/AU
E3	0 -->	GREENE J/AU
E4	1	GREENE J JERROLD/AU
E5	2	GREENE JACK C/AU
E6	1	GREENE JACK E/AU
E7	2	GREENE JACK T/AU
E8	3	GREENE JAMES A/AU
E9	1	GREENE JAMES ALBERT/AU
E10	1	GREENE JAMES B/AU
E11	1	GREENE JAMES D/AU
E12	1	GREENE JAMES E/AU

=> e greene jo/au

E1	1	GREENE JERRY/AU
E2	1	GREENE JIMMY D/AU
E3	0 -->	GREENE JO/AU
E4	1	GREENE JOE A/AU
E5	1	GREENE JOEL C/AU
E6	1	GREENE JOHATHAN W/AU
E7	2	GREENE JOHN/AU
E8	3	GREENE JOHN D/AU
E9	1	GREENE JOHN F/AU
E10	1	GREENE JOHN L/AU
E11	4	GREENE JOHN M/AU
E12	2	GREENE JOHN P/AU

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT
LOGOFF
LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS
SINCE FILE TOTAL

ENTRY	SESSION
FULL ESTIMATED COST	
37.55	37.70

STN INTERNATIONAL LOGOFF AT 00:30:26 ON 23
NOV 1998